Molluscum contagiosum

LiVDerm Set To Launch Its Brand-New Online MOPD Foundations of Pediatric Dermatology Certificate Course

Retrieved on: 
Wednesday, June 7, 2023
Learning, Certificate of Completion of Training, Arm, PAS, Dermatophytosis, Scabies, Impetigo, Catalog, Wart, Skin, Psoriasis, Dermatology, Student, Pediatrics, MD, Patient, Practitioner, Molluscum contagiosum, Adolescence, Knowledge, Diagnosis, Pityriasis rosea, Completion, Infantile hemangioma, Tutoring, Nursing

This innovative course consists of six in-depth modules that look at the most common pediatric skin conditions clinicians come face-to-face with on a daily basis.

Key Points: 
  • This innovative course consists of six in-depth modules that look at the most common pediatric skin conditions clinicians come face-to-face with on a daily basis.
  • What makes this course even more appealing to busy health care professionals is the fact that it is fully online and self-paced.
  • Led by world-renowned medical, aesthetic, and pediatric dermatology experts, LiVDerm empowers providers to educate, collaborate, and engage.
  • With a multipronged approach to mastering the myriad of subspecialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.

Novan Focuses Strategic Direction and Announces Restructuring

Retrieved on: 
Wednesday, May 31, 2023
Face, Stock dilution, NDA, Sale, Molluscum contagiosum, Novin, PDUFA, SB206, Bank

DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that following an evaluation of its commercial and developmental stage assets, it has decided to sharpen its focus and resources on berdazimer gel, 10.3% (SB206) and announced that it continues to explore strategic alternatives, with a focus on its commercial product portfolio and a sale or out-license of one or more of its commercial products.

Key Points: 
  • Novan conducted a deliberate and thorough review of its commercial and development portfolio of assets to determine a path to optimally deploy capital and maximize shareholder value.
  • Following this review, the Company, has initiated a process to explore a sale or out-license of its commercial assets, including RHOFADE, MINOLIRA, and CLODERM.
  • After careful consideration, we have made the strategic decision to implement a reduction in force of our commercial team and continue to explore a sale or out-license of our commercial assets.
  • The Company took this step to concentrate its resources on pursuing the regulatory approval for the Company’s berdazimer gel, 10.3% product candidate.

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 15, 2023
Ligand Pharmaceuticals, Rosacea, Advertising, EPI, Satō, Drug development, File, Marketing, Novin, NDA, Health, Nitric oxide, Prescription, Consultant, Acquisition, Molluscum contagiosum, PDUFA, Webcast, SB206, Growth, Research, FDA, Conference, Cryptocurrency, Pharmaceutical industry, Video game, Dermatology

DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update. The Company will host a conference call and webcast, today, May 15, 2023, at 8:30 a.m. ET (details below).

Key Points: 
  • ET –
    DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update.
  • “Turning to our commercial portfolio, the first quarter of 2023 marked a noteworthy increase in the number of new prescription writers across our promoted products.
  • 9% prescription growth in first quarter 2023 compared to first quarter 2022;
    26% increase in total writers in first quarter 2023 compared to first quarter 2022; and
    1% increase in units sold in first quarter 2023 compared to first quarter 2022.
  • 19% prescription growth in first quarter 2023 compared to first quarter 2022;
    18% increase in new prescriptions compared to first quarter 2022; and
    23% increase in units sold in first quarter 2023 compared to first quarter 2022.

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Therapy, Table, Bank statement, New Drug Application, CMC, NDA, GAAP, Part, H.262/MPEG-2 Part 2, Molluscum contagiosum, Dermatology, Treatment, PDUFA, Research, FDA, Carcinoma, Collaboration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology transfer, Food, Skin, Pharmaceutical industry, Bank

WEST CHESTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum
    WEST CHESTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2023.
  • “The first quarter of 2023 saw continued execution across our pipeline and strengthening of our financial position,” said Ted White, Verrica’s President and Chief Executive Officer.
  • On January 4, 2023, Verrica announced the successful completion of the technology transfer of bulk solution manufacturing of YCANTH to Piramal Pharma Solutions.
  • Costs of collaboration revenue were $68,000 for the first quarter of 2023, compared to $0.3 million for the same period in 2022.

Ligand Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, Telephone, Fulvestrant, GAAP, Congress, Investment, Focal segmental glomerulosclerosis, Patient, NYSE, PROTECT, Novartis, LGG, NASH, Mutation, Element, Forecasting, EMA, Proteinuria, Molluscum contagiosum, PDUFA, Growth, SB206, FDA, Lancet, THC, Total, Safety, Pelican, CDK, Microcystic lymphatic malformation, COVID-19, FSGS, BRAF, Immunoglobulin A, Research, Therapy, NVS, ESR1, NDA, Income tax, Woman, Sale, Trial of the century, Nephrology, Physician, EPS, Breast cancer, Cryptocurrency, Pharmaceutical industry, Travers Smith, Ligand, IgA nephropathy

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates.
  • Core Captisol sales were $10.6 million for the first quarter of 2023, compared with $6.2 million for the same period in 2022.
  • Contract revenue was $16.2 million for the first quarter of 2023, compared with $11.0 million for the same period in 2022.
  • Ligand is increasing 2023 revenue and EPS guidance provided on its fourth quarter earnings call held on February 22, 2023.

Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD

Retrieved on: 
Thursday, April 20, 2023
San Francisco, Society, Public health, Dermatitis, Doctor of Philosophy, MD, Molluscum contagiosum, Novin, SB206, Family, Dermatology

DURHAM, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host an Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD, on Tuesday, April 25, 2023, at 2:00 PM ET.

Key Points: 
  • DURHAM, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host an Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD, on Tuesday, April 25, 2023, at 2:00 PM ET.
  • He is a past-president for the Society for Pediatric Dermatology and is the immediate past president of the California Society of Dermatology.
  • In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event.
  • A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

Novan Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 30, 2023
Rosacea, EPI, Satō, Drug development, SG, File, Marketing, Novin, NDA, Health, Nitric oxide, Research, Research and development, Development, Acquisition, Molluscum contagiosum, PDUFA, Webcast, SB206, Growth, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Food, Pharmaceutical industry, Cryptocurrency, Video game, Dermatology

DURHAM, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the full year ended December 31, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, March 30, 2023, at 8:30 a.m. ET (details below).

Key Points: 
  • ET –
    DURHAM, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the full year ended December 31, 2022 and provided a corporate update.
  • As of December 31, 2022, Novan had a total cash and cash equivalents balance of $12.3 million.
  • Novan reported total revenue of $23.7 million and $3.0 million for the year ended December 31, 2022 and 2021, respectively.
  • 61% growth in 2022 compared to 2021;
    68% growth in fourth quarter 2022 compared to fourth quarter 2021; and
    13% decrease in fourth quarter 2022 compared to third quarter 2022.

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024

Retrieved on: 
Tuesday, March 7, 2023
Prescription Drug User Fee Act, Novin, Dermatology, FDA, NDA, Molluscum contagiosum, SB206, Marketing, New chemical entity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, File, Food, Pharmaceutical industry

DURHAM, N.C., March 07, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that the U.S. Food and Drug Administration (“FDA”) accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum (“molluscum”). The Company also received its Prescription Drug User Fee (“PDUFA”) goal date of January 5, 2024.

Key Points: 
  • The Company also received its Prescription Drug User Fee (“PDUFA”) goal date of January 5, 2024.
  • “The opportunity for our NDA to be approved in less than 10 months from today marks a significant and important milestone for Novan and its shareholders.
  • We believe our NCE can provide a much-needed therapeutic option for molluscum patients with the added benefit of being an easily applied, topical, self-administered treatment,” commented Paula Brown Stafford, President and Chief Executive Officer of Novan.
  • Novan’s commercial infrastructure includes a highly experienced sales and marketing team, supply chain capabilities, market access knowledge, medical affairs experts, and a network of related partners.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
Skin, New Drug Application, Dermatology, Therapy, CMC, Insurance, Cantharidin, Molluscum contagiosum, Table, Bank statement, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Part, GAAP, Patient, Pharmacokinetics, Food, Carcinoma, Collaboration, FDA, Research, Safety, WEST, PDUFA, Wart, Pharmaceutical industry, Vaccine, Cryptocurrency, Torii

WEST CHESTER, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Verrica expects to initiate Part 2 of its ongoing Phase 2 study in basal cell carcinoma in the second quarter of 2023.
  • Verrica reported a net loss of $5.9 million for the fourth quarter of 2022, compared to a $9.5 million loss for the same period in 2021.
  • Research and development expenses were $3.0 million in the fourth quarter of 2022, compared to $3.4 million for the same period in 2021.
  • General and administrative expenses were $3.2 million in the fourth quarter of 2022, compared to $5.1 million for the same period in 2021.

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

Retrieved on: 
Monday, February 27, 2023
Safety, PDUFA, Cantharidin, Prescription Drug User Fee Act, WEST, Skin, Molluscum contagiosum, GMP, FDA, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, NDA, Therapy, Food, Pharmaceutical industry

WEST CHESTER, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the Company’s resubmitted New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (“molluscum”) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 23, 2023.

Key Points: 
  • “We are pleased that the FDA has accepted for filing our NDA resubmission for VP-102,” said Ted White, Verrica’s President and Chief Executive Officer.
  • “With no FDA-approved treatments for molluscum, the filing acceptance of our NDA brings us one step closer towards providing a safe and effective therapeutic treatment option for the millions of patients in the United States with molluscum.
  • VP-102 has been designed for reliable and targeted administration of cantharidin through a unique, topical, GMP-controlled formulation through a single-use applicator.
  • Based upon the strong safety and efficacy results from our two Phase 3 clinical trials, we believe that VP-102 has the potential to offer an important new treatment option for molluscum.”